In patients with hypertrophic cardiomyopathy, the pooled 10-year survival rate is 75.0%, with NYHA class III/IV, non-sustained ventricular tachycardia, and left ventricular outflow tract obstruction serving as strong predictors of mortality.
No takes yet. Share an insight, caveat, or question.
Highlights the need for symptom and morphology-based risk stratification in hypertrophic cardiomyopathy;.
Liu et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: